Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of adjuvanted CHIKV VLP vaccine versus placebo for prevention of chikungunya disease in adolescents and older participants
2025-000501-16Phase 3
- Sponsor
- Bavarian Nordic
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chikungunya (CHIKV) comparing CHIKV VLP vaccine with Placebo (2 arms). Primary endpoint: Incidence of laboratory-confirmed acute chikungunya disease.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2025-000501-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000501-16.